

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, will present at the Piper Sandler 37th Annual Healthcare Conference, taking place December 2–4, 2025 at The Lotte New York Palace in New York City.

The Company’s presentation will highlight continued commercial momentum, clinical advancement across the MagnetOs portfolio, and ongoing expansion in new indications and the global market. Kuros will also provide insights into its path to sustainable profitability and operational leverage through the transformation of its business model, supported by recent investments in operational infrastructure designed to secure long-term growth.

A live webcast of the presentation will be available on the Piper Sandler conference website for 30 days following the event: <https://statusproconf.com/Agenda/event/2091>

Presentation Details

Event: Piper Sandler 37th Annual Healthcare Conference

Presenter: Chris Fair, CEO, Kuros Biosciences

Format: Company Presentation

Date: Wednesday, December 3, 2025

Location: The Lotte New York Palace, New York, NY

For more information about the conference, please visit Piper Sandler’s website at: <https://www.pipersandler.com/>

For further information, please contact:

Alexandre Müller
Investor Relations
Tel +41 43 268 32 31
IR@kurosbio.com

Daniel Geiger
Chief Financial Officer
Tel +41 44 733 47 41
daniel.geiger@kurosbio.com

About MagnetOs

Growing bone with MagnetOs™ gives surgeons confidence where it matters most – delivering predictable fusion outcomes.¹ In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate of autograft (79% vs. 47%) in posterolateral

fusions (PLFs).¹ Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic.^{+1,2} MagnetOs grows bone on its own thanks to NeedleGrip™ – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors.^{§,4-6} Ready-to-use, easy to mold, and reliably staying put, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures.^{¶7-12}*

Indications Statement

Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions.

About Kuros Biosciences

Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOs™, is a unique advanced bone graft that has already been used across five continents. For more information on the company, its products and pipeline, visit kurosbio.com.

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

* 19 of initial 100 patients were active smokers.

† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.

‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.

§ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.

¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space.

1. Stempels, et al. *Spine*. 2024;49(19):1323-1331.
2. Van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024.
3. Data on file. MagnetOs Putty and MagnetOs Easypack Putty.
4. Van Dijk, et al. *eCM*. 2021;41:756-73.
5. Van Dijk, et al. *J Immunol Regen Med*. 2023;19:100070.
6. Duan, et al. *eCM*. 2019; 37:60-73.
7. Instructions for Use (IFU) MagnetOs Granules.

8. Instructions for Use (IFU) MagnetOs Putty.
9. Instructions for Use (IFU) MagnetOs Easypack Putty.
10. Instructions for Use (IFU) MagnetOs Flex Matrix.
11. Instructions for Use (IFU) MagnetOs MIS.
12. Data on file. MagnetOs Putty and MagnetOs Easypack Putty